AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Bayer aktiengesellschaft11/17/2023 ![]() “As part of our strategy, we are building new therapeutic platforms including cell and gene therapies,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division. “With this acquisition, Bayer significantly advances the establishment of a cell and gene therapy platform that can be at the forefront of breakthrough science contributing to, preventing, or even curing diseases caused by gene defects and further driving company growth in the future.” “In line with our purpose ‘science for a better life,’ we are committed to bringing significant improvements for patients through innovation,” said Werner Baumann, Chairman of the Board of Management (CEO) of Bayer AG. Some 75 percent of the potential milestone-based contingent payments are expected to be due during the course of the next five years and the remaining amount thereafter. ![]() Under the terms of the agreement, Bayer will pay upfront consideration of USD 2 billion and potential success-based milestone payments of up to USD 2 billion. It complements its 2019 acquisition of BlueRock Therapeutics and advances Bayer’s efforts to create platforms with the potential to have an impact in multiple therapeutic areas. The addition of AskBio to Bayer’s emerging cell and gene therapy (CGT) business strengthens Bayer’s commitment to the field. AskBio’s development portfolio includes investigational pre-clinical and clinical-stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.Īs a result of the acquisition, Bayer will own AskBio’s gene therapy platform, including a broad intellectual property portfolio and established contract development and manufacturing organization (CDMO), laying the foundation for future partnerships in the area of adeno-associated virus (AAV) therapies. (AskBio) today announced an agreement under which Bayer will acquire AskBio, a U.S.-headquartered biopharmaceutical company specializing in the research, development and manufacturing of gene therapies across different therapeutic areas. – Octo– Bayer AG and Asklepios BioPharmaceutical, Inc. – Purchase price of USD 2 billion upfront and up to USD 2 billion in success-based milestone payments –īerlin, Germany and Research Triangle Park, N.C. – AskBio to operate autonomously and on an arm’s-length basis – – Acquisition secures additional revenue-generating CDMO based on highly efficient Pro10™ cell line – – Portfolio includes pre-clinical and clinical-stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as Pompe disease, Parkinson’s disease and congestive heart failure, as well as out-licensed clinical candidates for hemophilia and Duchenne muscular dystrophy – – AskBio’s industry leading AAV-based gene therapy platform already yielding commercial and clinical-stage assets with the potential to help larger patient populations – – Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need – With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.Back to all Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact. Science For a Better Live - Annual Report 2004Ĭorporate Social Responsibility Website and Sustainable Development Report Science For A Better Live -Sustainable Development Report 2005 Science For A Better Life - Bayer Sustainable Development Report 2006 Science For A Better Life - Sustainable Development Report 2007 2021 Bayer Communication on Progress: Bayer Sustainability ReportĢ018 Bayer Communication on Progress: Bayer Annual Report 2018Ģ017 Bayer Communication on Progress ( Annual Report Augmented Version)Ģ016 Bayer Communication on Progress (Annual Report Augmented Version plus Bayer UNGC Blueprint Report)Ģ015 Bayer Communication on Progress (Annual Report Augmented Version plus Bayer UNGC Blueprint Report)Ģ014 Bayer Communication on Progress (Annual Report Augmented Version plus Bayer UNGC Blueprint Report)Ģ013 Communication on Progress Bayer (Annual Report Augmented Version plus Bayer UNGC Blueprint Report)Ĭommunication on Progress 2012 (Bayer SD Report 2012 with comprehensive Blueprint Progress Report PDF)Ģ012 Bayer UNGC Communication on Progressīayer: Science For A Better Life - Sustainable Development Report 2008
0 Comments
Read More
Leave a Reply. |